[{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"CEP-37251","moa":"\nRANKL","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Obatoclax Mesylate","moa":"Apoptosis regulator Bcl-W | Apoptosis regulator Bcl-2 | Bcl-2-like protein 10 | Bcl-2-related protein A1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Apoptosis regulator Bcl-X","graph1":"Oncology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"CEPHALON INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"CEPHALON INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Oncology","graph2":"Undisclosed","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"1","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Neurology","graph2":"Undisclosed","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"1","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nephrology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CEP-9722","moa":"Poly [ADP-ribose] polymerase (PARP)","graph1":"Oncology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"CEPHALON INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"CAS 26833-87-4","moa":"Protein biosynthesis","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"CEPHALON INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ CEPHALON INC","highestDevelopmentStatusID":"8","companyTruncated":"CEPHALON INC \/ CEPHALON INC"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"CEP-37247","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Robert Redner, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CEPHALON INC \/ Robert Redner, MD","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Robert Redner, MD"}]
Find Clinical Drug Pipeline Developments & Deals by CEPHALON INC
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
